Search - tctmd.com

Displaying 241 - 260 of 440

Sort: Relevancy | Date

Presentation TCT 2013

Moderate Treatment Resistant Hypertension: A New Indication for RDN?

Presenter: David Kandzari

October 27, 2013

Presentation TCT 2013

Mesenteric Ischemia Syndromes and Treatments: An Update

Presenter: Greg Mishkel

October 27, 2013

Presentation TCT 2013

Is the Noncompliant Patient with Severe Treatment Resistant Hypertension an Appropriate Candidate for this Technology?

Presenter: Robert Whitbourn

October 27, 2013

Presentation TCT 2013

Is Renal Denervation REALLY READY for Prime Time: A Critical Appraisal

Presenter: Darrel Francis

October 27, 2013

Presentation TCT 2013

How We Should Define "Responsiveness" to Renal Denervation Therapies

Presenter: Krishna Rocha-Singh

October 27, 2013

Presentation TCT 2013

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Presenter: Andrew Farb

October 27, 2013

Presentation TCT 2013

Extra-vascular Focused Ultrasonic Denervation (Kona Medical)

Presenter: Todd Brinton

October 27, 2013

Presentation TCT 2013

Ethanol Injection for Renal Denervation (Ablative Solutions)

Presenter: Tim Fischell

October 27, 2013

Presentation TCT 2013

Electrophysiological Considerations for Renal Denervation: Implications for Arrhythmia Control

Presenter: Vivek Reddy

October 27, 2013

Presentation TCT 2013

Discussion with Audience Q&A

Presenter: Ariel Sverdlik

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Vessix (Boston Scientific)

Presenter: Ajay Kirtane

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Presenter: David Kandzari

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Paradise (ReCor Medical)

Presenter: Thomas Zeller

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: OneShot (Covidien)

Presenter: John Ormiston

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: EnligHTN (St. Jude)

Presenter: Stephen Worthley

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Cordis Renal Denervation Approach

Presenter: Marc Sapoval

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Allegro/Iberis (Angiocare/Terumo)

Presenter: Xiongjing Jiang

October 27, 2013

Presentation TCT 2013

Cost-Effectiveness of Catheter-Based Renal Denervation in Severe Treatment Resistant Hypertension

Presenter: Jan Pietzsch

October 27, 2013

Presentation TCT 2013

Cost-Effectiveness Considerations for Mild and Moderate Hypertension

Presenter: Mark Hlatky

October 27, 2013

Presentation TCT 2013

Chemical Ablation for Renal Denervation (Northwind Technologies)

Presenter: Mark Wholey

October 27, 2013

Advertisement

Moderate Treatment Resistant Hypertension: A New Indication for RDN?

Mesenteric Ischemia Syndromes and Treatments: An Update

Is the Noncompliant Patient with Severe Treatment Resistant Hypertension an Appropriate Candidate for this Technology?

Is Renal Denervation REALLY READY for Prime Time: A Critical Appraisal

How We Should Define "Responsiveness" to Renal Denervation Therapies

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Extra-vascular Focused Ultrasonic Denervation (Kona Medical)

Ethanol Injection for Renal Denervation (Ablative Solutions)

Electrophysiological Considerations for Renal Denervation: Implications for Arrhythmia Control

Discussion with Audience Q&A

Device and Clinical Trial Update: Vessix (Boston Scientific)

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Device and Clinical Trial Update: Paradise (ReCor Medical)

Device and Clinical Trial Update: OneShot (Covidien)

Device and Clinical Trial Update: EnligHTN (St. Jude)

Device and Clinical Trial Update: Cordis Renal Denervation Approach

Device and Clinical Trial Update: Allegro/Iberis (Angiocare/Terumo)

Cost-Effectiveness of Catheter-Based Renal Denervation in Severe Treatment Resistant Hypertension

Cost-Effectiveness Considerations for Mild and Moderate Hypertension

Chemical Ablation for Renal Denervation (Northwind Technologies)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content